FRM
SPRY icon

Fox Run Management’s ARS Pharmaceuticals SPRY Stock Holding History

Fox Run Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$258K Buy
+59,793
New +$350K 0.03% 799
2026
Q1 		– Sell
-38,587
Closed -$450K – 1217
2025
Q4 		$450K Buy
+38,587
New +$375K 0.07% 542
2023
Q3 		– Sell
-22,992
Closed -$154K – 978
2023
Q2 		$154K Buy
+22,992
New +$153K 0.04% 610

Other funds holding SPRY

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Tyro Capital Management
Tyro Capital Management Miami, Florida $564M AUM 72.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $52.3B AUM 19.7% 1-Year Est. Return
Creek Drive Management Group
Creek Drive Management Group San Francisco, California $368M AUM 23.05% 1-Year Est. Return

Fox Run Management's SPRY Position: Q3 2026 in Review

Fox Run Management opened a new position in ARS Pharmaceuticals (SPRY) in Q3 2026: 59,793 shares worth $258K. The stake represents 0.03% of the portfolio and ranks #799 among its holdings. This is a return to the name: Fox Run Management previously reported a position in SPRY as recently as Q4 2025.

Fox Run Management first reported a position in SPRY in Q2 2023 and has held it in 3 quarters since. The position peaked at $450K in Q4 2025. 133 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.

  • Fox Run Management held 59,793 shares of ARS Pharmaceuticals worth $258K as of Q3 2026.
  • ARS Pharmaceuticals was a new Fox Run Management position in Q3 2026.
  • ARS Pharmaceuticals made up 0.03% of Fox Run Management's portfolio in Q3 2026, its #799 holding.
  • Fox Run Management first reported a position in ARS Pharmaceuticals in Q2 2023 and has held it in 3 quarters since.
  • Fox Run Management's ARS Pharmaceuticals position peaked at $450K in Q4 2025.
  • 133 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.

Based on Fox Run Management's 13F filing for Q3 2026, filed 12 Nov 2026.